US2018280317A1PendingUtilityA1

Methods and devices for using isoperillyl alcohol

57
Assignee: NEONC TECH INCPriority: Dec 17, 2010Filed: Jun 4, 2018Published: Oct 4, 2018
Est. expiryDec 17, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Thomas ChenDaniel LevinSatish PupalliDaniel Anthony Dickman
A61P 43/00A61P 35/00A61K 47/54C07B 2200/07C07D 207/26A61K 31/4015A61K 31/165C07C 269/00A61K 45/06A61K 31/415A61K 31/045A61K 47/55C07C 271/22A61K 31/325C07D 487/04A61K 31/27A61K 31/4188C07D 231/12A61K 31/635A61P 25/00A61N 5/10A61K 31/05A61K 2300/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a disease in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of an isoperillyl alcohol. 
     
     
         2 . The method of  claim 1 , wherein the isoperillyl alcohol is selected from the group consisting of (4-isopropylidene cyclohex-1-enyl)methanol, (4-isopropyl cyclohexa-1,3-dienyl)methanol, (4-isopropyl cyclohexa-1,4-dienyl)methanol, (4-isopropylphenyl)methanol and (4-isopropenylphenyl)methanol. 
     
     
         3 . The method of  claim 1 , wherein the disease is cancer. 
     
     
         4 . The method of  claim 3 , wherein the cancer is a tumor of the nervous system. 
     
     
         5 . The method of  claim 4 , wherein the tumor is a glioblastoma. 
     
     
         6 . The method of  claim 1 , further comprising the step of treating the mammal with radiation. 
     
     
         7 . The method of  claim 6 , wherein the isoperillyl alcohol is administered before, during or after radiation. 
     
     
         8 . The method of  claim 1 , further comprising the step of administering to the mammal a chemotherapeutic agent. 
     
     
         9 . The method of  claim 8 , wherein the isoperillyl alcohol is administered before, during or after the administration of the chemotherapeutic agent. 
     
     
         10 . The method of  claim 1 , wherein the isoperillyl alcohol is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         11 . A method for treating a disease in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of an isoperillyl alcohol carbamate. 
     
     
         12 . The method of  claim 11 , wherein the disease is cancer. 
     
     
         13 . The method of  claim 12 , wherein the cancer is a tumor of the nervous system. 
     
     
         14 . The method of  claim 13 , wherein the tumor is a glioblastoma. 
     
     
         15 . The method of  claim 11 , further comprising the step of treating the mammal with radiation. 
     
     
         16 . The method of  claim 11 , further comprising the step of administering to the mammal a chemotherapeutic agent. 
     
     
         17 . The method of  claim 11 , wherein the isoperillyl alcohol carbamate is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         18 . The method of  claim 11 , wherein the isoperillyl alcohol carbamate is an isoperillyl alcohol conjugated with a therapeutic agent. 
     
     
         19 . The method of  claim 18 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         20 . The method of  claim 19 , wherein the chemotherapeutic agent is selected from the group consisting of a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist. 
     
     
         21 . The method of  claim 18 , wherein the therapeutic agent is selected from the group consisting of dimethyl celocoxib (DMC), temozolomide (TMZ) and rolipram. 
     
     
         22 . A method for treating a disease in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of an isoperillyl alcohol or an isoperillyl alcohol carbamate using a nasal delivery device. 
     
     
         23 . The method of  claim 22 , wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a squeeze bottle and a bi-directional device. 
     
     
         24 . A pharmaceutical composition comprising an isoperillyl alcohol carbamate. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the isoperillyl alcohol carbamate is an isoperillyl alcohol conjugated with a therapeutic agent. 
     
     
         26 . The pharmaceutical composition of  claim 25 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         27 . The pharmaceutical composition of  claim 25 , wherein the therapeutic agent is selected from the group consisting of dimethyl celocoxib (DMC), temozolomide (TMZ) and rolipram. 
     
     
         28 . The pharmaceutical composition of  claim 25 , wherein the chemotherapeutic agent is selected from the group consisting of a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist. 
     
     
         29 . The pharmaceutical composition of  claim 24 , wherein the pharmaceutical composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         30 . The pharmaceutical compoMtion of  claim 24 , wherein the pharmaceutical composition is admixed or coformulated with a therapeutic agent. 
     
     
         31 . A pharmaceutical composition comprising an isoperillyl alcohol admixed or coformulated with a therapeutic agent. 
     
     
         32 . A process for making an isoperillyl alcohol carbamate, comprising the step of reacting a first reactant of isoperillyl chloroformate with a second reactant selected from the group consisting of dimethyl celocoxib (DMC), temozolomide (TMZ) and rolipram. 
     
     
         33 . The process of  claim 32 , wherein the second reactant is dimethyl celocoxib. 
     
     
         34 . The process of  claim 32 , wherein the reaction is carried out in the presence of acetone and a catalyst of potassium carbonate. 
     
     
         35 . The process of  claim 32 , wherein the second reactant is rolipram. 
     
     
         36 . The process of  claim 35 , wherein the reaction is carried out in the presence of tetrahydrofuran and a catalyst of n-butyl lithium. 
     
     
         37 . The process of  claim 32 , wherein isoperillyl chloroformate is prepared by reacting isoperillyl alcohol with phosgene.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.